Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07119918) titled 'PCSK9 Inhibitor for Intracranial Atherosclerotic Symptomatic Stenosis' on Aug. 6.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Condition: Symptomatic Intracranial Atherosclerotic Stenosis

Intervention: Drug: Recaticimab

Recruitment Status: Not recruiting

Phase: Phase 3

Date of First Enrollment: September 1, 2025

Target Sample Size: 5276

Countries of Recruitment:...